Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
6.99
-0.46 (-6.17%)
May 30, 2025, 3:12 PM - Market open
Intellia Therapeutics Revenue
Intellia Therapeutics had revenue of $16.63M in the quarter ending March 31, 2025, a decrease of -42.54%. This brings the company's revenue in the last twelve months to $45.57M, down -13.37% year-over-year. In the year 2024, Intellia Therapeutics had annual revenue of $57.88M with 59.55% growth.
Revenue (ttm)
$45.57M
Revenue Growth
-13.37%
P/S Ratio
16.49
Revenue / Employee
$113,074
Employees
403
Market Cap
724.05M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 57.88M | 21.60M | 59.55% |
Dec 31, 2023 | 36.28M | -15.85M | -30.40% |
Dec 31, 2022 | 52.12M | 19.07M | 57.69% |
Dec 31, 2021 | 33.05M | -24.94M | -43.01% |
Dec 31, 2020 | 57.99M | 14.89M | 34.55% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
NTLA News
- 1 day ago - Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course - Benzinga
- 10 days ago - I Missed The Quantum Rally - I Won't Miss The Next One - Seeking Alpha
- 12 days ago - Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting - GlobeNewsWire
- 16 days ago - Intellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript) - Seeking Alpha
- 18 days ago - Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade) - Seeking Alpha
- 22 days ago - Intellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 25 days ago - CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts - Seeking Alpha